This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, L. Articles by Wang, L. Search for Related Content PubMed PubMed Citation Articles by Li, L. Articles by Wang, L.

Gemcitabine and Cytosine Arabinoside Cytotoxicity: Association with Lymphoblastoid Cell Expression

Departments of ¹ Molecular Pharmacology and Experimental Therapeutics and ² Health Sciences Research, Mayo Clinic, Rochester, Minnesota

Requests for reprints: Liewei Wang, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-284-5264; Fax: 507-284-4455; E-mail: wang.liewei{at}mayo.edu.

Key Words: cytidine analogues • gemcitabine • dFdC • 1-β-D-arabinofuranosylcytosine • AraC • lymphoblastoid cell lines • expression array • 5'-nucleotidase • cytosolic III nucleotidase • NT5C3 • FK506 binding protein 5 • FKBP5 and Ingenuity Pathway Analysis

Two cytidine analogues, gemcitabine (dFdC) and 1-β-D-arabinofuranosylcytosine (AraC), show significant therapeutic effect in a variety of cancers. However, response to these drugs varies widely. Evidence from tumor biopsy samples shows that expression levels for genes involved in the cytidine transport, metabolism, and bioactivation pathway contribute to this variation in response. In the present study, we set out to test the hypothesis that variation in gene expression both within and outside of this "pathway" might influence sensitivity to gemcitabine and AraC. Specifically, Affymetrix U133 Plus 2.0 GeneChip and cytotoxicity assays were performed to obtain basal mRNA expression and IC₅₀ values for both drugs in 197 ethnically defined Human Variation Panel lymphoblastoid cell lines. Genes with a high degree of association with IC₅₀ values were involved mainly in cell death, cancer, cell cycle, and nucleic acid metabolism pathways. We validated selected significant genes by performing real-time quantitative reverse transcription-PCR and selected two representative candidates, NT5C3 (within the pathway) and FKBP5 (outside of the pathway), for functional validation. Those studies showed that down-regulation of NT5C3 and FKBP5 altered tumor cell sensitivity to both drugs. Our results suggest that cell-based model system studies, when combined with complementary functional characterization, may help to identify biomarkers for response to chemotherapy with these cytidine analogues. [Cancer Res 2008;68(17):7050–8]

This article has been cited by other articles:

				M. Welsh, L. Mangravite, M. W. Medina, K. Tantisira, W. Zhang, R. S. Huang, H. McLeod, and M. E. Dolan Pharmacogenomic Discovery Using Cell-Based Models Pharmacol. Rev., December 1, 2009; 61(4): 413 - 429. [Abstract] [Full Text] [PDF]

				N. Niu, V. Manickam, K. R. Kalari, I. Moon, L. L. Pelleymounter, B. W. Eckloff, E. D. Wieben, D. J. Schaid, and L. Wang Human Glucocorticoid Receptor {alpha} Gene (NR3C1) Pharmacogenomics: Gene Resequencing and Functional Genomics J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 3072 - 3084. [Abstract] [Full Text] [PDF]

				L. Wang and R. M. Weinshilboum Pharmacogenomics: candidate gene identification, functional validation and mechanisms Hum. Mol. Genet., October 15, 2008; 17(R2): R174 - R179. [Abstract] [Full Text] [PDF]